Daniele D’Ambrosio joined Galapagos in 2018 and was appointed Senior VP, Immunology Therapeutic Area Head in 2022. In this role, Daniele is responsible for scientific leadership and management of the discovery and clinical development of Galapagos’ immunology assets. Prior to joining Galapagos, Daniele held various R&D positions in biotech and leading pharmaceutical companies including Roche, Novartis, Actelion, and Johnson & Johnson. During his tenure, he helped developing novel treatments for autoimmune diseases including ponesimod (Ponvory®), canakinumab (Ilaris®), and filgotinib (Jyseleca®).
Daniele earned his M.D. and Ph.D. in Experimental Medicine and Immunology from La Sapienza University, Rome, Italy. He completed a postdoctoral fellowship in Immunology at the National Jewish Hospital in Denver, has published more than 60 scientific articles, and is inventor on one issued patent. Daniele has served on the Editorial Board of British Journal of Pharmacology, and held a Professorship at the School of Medical, Molecular and Cellular Biotechnologies at Vita Salute San Raffaele University, Milano, Italy.